Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug Administration